Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Analysts

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been given an average recommendation of “Moderate Buy” by the eight research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $32.80.

GLUE has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $31.00 target price on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. TD Cowen reissued a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Finally, Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st.

Insider Buying and Selling at Monte Rosa Therapeutics

In related news, insider Edmund Dunn sold 25,164 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $18.10, for a total value of $455,468.40. Following the transaction, the insider owned 22,693 shares in the company, valued at $410,743.30. This trade represents a 52.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $17.92, for a total value of $97,950.72. Following the sale, the chief executive officer directly owned 613,471 shares of the company’s stock, valued at $10,993,400.32. This represents a 0.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 36,771 shares of company stock valued at $693,692 over the last three months. Insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GLUE. GAMMA Investing LLC bought a new stake in shares of Monte Rosa Therapeutics in the 4th quarter valued at $30,000. Russell Investments Group Ltd. acquired a new position in Monte Rosa Therapeutics in the third quarter valued at about $32,000. Lazard Asset Management LLC increased its holdings in shares of Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after acquiring an additional 3,262 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after acquiring an additional 451 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares during the period. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE opened at $15.38 on Friday. The stock’s 50 day simple moving average is $18.76 and its 200 day simple moving average is $15.35. Monte Rosa Therapeutics has a one year low of $3.50 and a one year high of $25.77. The firm has a market cap of $1.23 billion, a PE ratio of -33.43 and a beta of 1.63.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). The business had revenue of $2.78 million during the quarter, compared to analyst estimates of $17.09 million. Monte Rosa Therapeutics had a negative return on equity of 15.12% and a negative net margin of 31.23%. As a group, equities analysts expect that Monte Rosa Therapeutics will post -1.49 earnings per share for the current year.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.